A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932

Oncology

Volumn 69, Issue 2, 2005, Pages 117-121

  Perez, Edith A ^a,i   Suman, Vera J ^a   Fitch, Tom R ^b   Mailliard, James A ^c   Ingle, James N ^a   Cole, John T ^d   Veeder, Michael H ^e   Flynn, Patrick J ^f   Walsh, Daniel J ^g   Addo, Ferdinand K ^h  

^a MAYO CLINIC   (United States)

^b Scottsdale CCOP   (United States)

^c Missouri Valley Cancer Center   (United States)

^d Ochsner CCOP   (United States)

^e Illinois Oncol Res Assoc CCOP   (United States)

^f Metro Minnesota Community Clinical Oncology Program   (United States)

^g Aitru Cancer Center   (United States)

^h SANFORD RESEARCH   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

Breast cancer; Carboplatin; Clinical trial; Docetaxel

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; PLATINUM; TAXANE DERIVATIVE;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY REACTION; INFECTION; LEUKOPENIA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 25444458878     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087813     Document Type: Article

References (20)

1. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-322.
2. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol 1996;7:165-171.
3. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: A new, highly effective anti-neoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-2894.
4. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58-65.
5. Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996;14:422-428.
6. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Br J Cancer 1996;74:650-656.
7. 2 as second-line chemotherapy in advanced breast cancer (abstract). Breast Cancer Res Treat 2002;76(suppl 1):88.
8. Smith IE, Talbot DC: Cisplatin and its analogues in the treatment of advanced breast cancer: A review. Br J Cancer 1992;65:787-793.
9. Gainford C, O'Leary M, El-Fiki T, Azil N, Rowan S, Kenny P, Ballot J, Flynn C, Fumoleau P, Kerbrat P, Fennelly D, Crown J: Phase I trial of docetaxel (T) and cisplatin (P) as first-line chemotherapy for metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 2000;19:113.
10. Spielmann M, Llombart A, Zelek L, Sverdlin R, Rixe O, Le Cesne A: Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol 1999;10:1457-1460.
11. Antoine EC, Meric JB, Coeffic D, Khallel N, Auclerc G, Nizri D, Delgado M, Rocher MA, Weil M, Merle S, Khayat D: Anthracycline-primary resistant breast cancer (APRBC): Confirmatory results of the high level of activity of the docetaxel (D)-cisplatin (C) regimen (abstract). Proc Am Soc Clin Oncol 1999;18:129.
12. Prescia V, Bordenave H, Foglia S, Litchvaky A, Wull F, Belloqui D, Gramuglia M, Arteaga CL: Taxotere (T) and cisplatin (P) in anthracycline- pretreated advanced breast cancer (ABC); preliminary results (abstract). Proc Am Soc Clin Oncol 2000;19:117.
13. Kariya S, Ogawa Y, Nishioka A, Yoshida S: Docetaxel-cisplatin combined chemotherapy in Japanese patients with anthracycline-pre-treated advanced breast cancer. Oncol Rep 2002;9:1345-1349.
14. Mavroudis D, Alexopoulos A, Malamos N, Ardavanis A, Kandylis C, Stavrinidis E, Kouroussis C, Agelaki S, Androulakis N, Bozionelou V, Georgoulias V: Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. Oncology 2003;64:207-212.
15. Alberti AM: A phase II study of docetaxel (T) and carboplatin (CPB) as second-line chemotherapy in metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 2000;19:113.
16. Perez EA, Hillman DW, Stella PJ, Krook JE, Hartmann LC, Fitch TR, Hatfield AK, Mailhard JA, Nair S, Kardinal CG, Ingle JN: A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000;88:124-131.
17. Fountzilas G, Dimopoulos AM, Papadimitriou C, Kalogera-Fountzila A, Aravantinos G, Bafaloukos D, Athanassiades A, Nicolaides C, Keramopoulos A, Pavlidis N, Kosmidis P, Skarlos D: First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1998;9:1031-1034.
18. Loesch DM, Robert NJ, Keller AM, et al: Phase II multicenter trial of a weekly taxol, 5-fluorouracil and leucovorin regimen in patients with metastatic breast cancer: A phase II trial (abstract 593). Proc Am Soc Clin Oncol 1998;17:155a.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
20. Kaplan E, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:456-481.